The global Breast Biopsy Devices market in terms of revenue was estimated to be worth $18.4 million in 2022 and is poised to reach $24.5 million by 2030, growing at a CAGR of 6.0% from 2023 to 2030. Breast tissue or cells are removed during a biopsy to check for cancer or other breast-related disorders. Cancers of the breast are typically detected through a breast biopsy. A breast biopsy may be recommended by the doctor if the patient is a woman who has never before experienced breast lumps. A breast biopsy may be recommended if a doctor notices abnormal changes in the breast, such as cellulite, hardening, scaling, or crusting of the skin. A breast biopsy may be recommended if a mammogram, ultrasound, or MRI reveals an area or region in the breast consistent with a lump in the breast or in a nearby lymph node.
Request a Sample Report @ https://www.coherentmarketinsights.com/insight/request-sample/123
PDF report & online dashboard will help you understand:
• Competitive Landscape
• Historical data & forecasts
• Company revenue shares
• Regional assessment
• Latest trends & dynamics
Breast cancer, or breast lesions that look suspicious and may need a biopsy, become more common as women get older. In comparison to other diagnostic tools like x-ray, ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI), vacuum-assisted breast biopsies (VABB) are widely used because of their low cost and quick response time. For instance, VABB is responsible for 90% of sales for breast biopsy devices made by Hologic, C.R. Bard, and Mammotome Company. The rising level of awareness is another factor propelling the market for breast biopsy devices. Men and women are encouraged by the American Cancer Society, Inc. to participate in self-exams held periodically throughout the year to detect any changes in their breast health prior to visiting a doctor for a formal diagnosis. Exposure to toxic chemicals has been linked to a rise in the prevalence of breast cancer. Approximately 50,000 American workers end up dying each year from the effects of exposure to dangerous substances, as reported by OSHA and NIOSH. However, the high price of the procedure and potential complications like bleeding and infections afterward are slowing the expansion of the breast biopsy device market.
Product, procedure, technology, end user, and geographic segments all play a role in the global breast biopsy devices market’s breakdown. Markets can be broken down into those for biopsy needles, biopsy tables, biopsy wires, and guidance systems.
Fine needle aspiration (FNA) biopsy, core needle biopsy, surgical biopsy, and biopsy markers make up the four major submarkets in this market. Surgical biopsies can be subdivided into incisional biopsies and excisional biopsies, while core needle biopsies can be further subdivided into stereotactic core needle biopsies, vacuum-assisted biopsies, and magnetic resonance imaging biopsy guidance.
The market is segmented into ultrasound-guided, mammography-guided, and magnetic resonance-guided subsets, depending on the type of guidance technology used.
The market is segmented based on the end user, which includes healthcare facilities such as hospitals, research laboratories, ambulatory surgical centers, diagnostic centers, and others.
North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa are the regions broken down by Coherent Market Insights. The United States and Canada both have large shares of the market because they were early adopters of cutting-edge medical technology. In 2015, there were more than 2.3 Mn new cases of breast cancer in the United States, according to Susan G. Komen, a nonprofit organization dedicated to raising awareness of the disease. The European Breast Cancer Coalition reports that in the EU-28 there were 361,600 new cases of breast cancer in 2012, and that one in eight European women will be diagnosed with breast cancer before the age of 85. Due to a sizable potential customer base (including many elderly people whose immune systems are less robust) and widespread adoption of VABB devices for breast cancer diagnosis, Europe is the world’s second-largest market. A large population base, rising per capita incomes, and rising levels of education all point to Asia Pacific becoming a promising market in the not-too-distant future. Over 39% of all breast cancers diagnosed worldwide in 2012 were in Asia, where over 600,000 new cases were reported, as reported by the International Association of Cancer Registries.
Limited Period Offer | Report Available Now at UP TO 45% off Discounted Pricing @
Single User License : https://www.coherentmarketinsights.com/promo/buynow/123
Multi Users License : https://www.coherentmarketinsights.com/promo/buynow/123
Corporate Users License : https://www.coherentmarketinsights.com/promo/buynow/123
Biomed Diagnostics, Inc., Bard Peripheral Vascular Inc., F. Hoffmann-La Roche Ltd., Hologic Inc., Intact Medical, Mammotome, OncoCyte Corporation, and Laboratory Corporation of America Holdings (Labcorp) are just a few of the major players in the breast biopsy devices market. In order to increase profits, the market’s leading companies are always looking for ways to introduce new products and reduce production costs. For instance, C. R. Bard has recently broadened the applicability of its devices by including free reusable biopsy handles with the acquisition of disposable biopsy needles.
First, the market’s leading firms adopted a number of strategic approaches, including mergers and acquisitions, to strengthen their foothold in the industry. For example, in December of 2017, the medical technology firm Becton, Dickinson and Company paid US$ 16 million to acquire C.R. Bard, Inc. The purchase means better care for patients with life-threatening diseases like cancer.
Second, to increase their market share, the market’s largest players adopted a variety of business strategies, including product launches. Examples include the Brevera breast biopsy system, developed by Hologic Inc. of the United States and utilizing CorLumina technology. Innovating the entire biopsy procedure, this new system will be a huge boon.
Third, market leaders adopted various business strategies, such as securing regulatory approvals, to increase their product offerings and strengthen their foothold in the industry. Example: In August of 2017, OncoCyte Corporation, a company that creates tests for detecting cancer, announced that its clinical laboratory had been approved for CLIA certification and State Clinical Laboratory Licensing by the California Department of Public Health Laboratory Field Services.
Request For Customization at: https://www.coherentmarketinsights.com/insight/request-customization/123
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Breast Biopsy Devices Market Size Analysis from 2023 to 2030
11.6 COVID-19 Outbreak: Breast Biopsy Devices Industry Impact
Chapter 2 Global Breast Biopsy Devices Competition by Types, Applications, and Top Regions and Countries
2.1 Global Breast Biopsy Devices (Volume and Value) by Type
2.3 Global Breast Biopsy Devices (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Breast Biopsy Devices Sales, Consumption, Export, Import by Regions (2017-2030)
Chapter 5 North America Breast Biopsy Devices Market Analysis
Chapter 6 East Asia Breast Biopsy Devices Market Analysis
Chapter 7 Europe Breast Biopsy Devices Market Analysis
Chapter 8 South Asia Breast Biopsy Devices Market Analysis
Chapter 9 Southeast Asia Breast Biopsy Devices Market Analysis
Chapter 10 Middle East Breast Biopsy Devices Market Analysis
Chapter 11 Africa Breast Biopsy Devices Market Analysis
Chapter 12 Oceania Breast Biopsy Devices Market Analysis
Chapter 13 South America Breast Biopsy Devices Market Analysis
Chapter 14 Company Profiles and Key Figures in Breast Biopsy Devices Business
Chapter 15 Global Breast Biopsy Devices Market Forecast (2023-2030)
Chapter 16 Conclusions
Coherent Market Insights is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Coherent Market Insights has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We at Coherent are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defence, among different ventures present globally.
Contact Us :
Coherent Market Insights
533 Airport Boulevard, Suite 400,
Burlingame, CA 94010, United States.